Contents

| 1. | Intro | oduction | 1 | | |
|----|----------------|--|--------|--|--|
| 2. | The disease | | | | |
| | 2.1 | Clinical signs and symptoms | 5 | | |
| | | 2.1.1 Signs and symptoms in the first stage | 5 8 | | |
| | 2.2 | 2.1.2 Signs and symptoms in the second stage | 9 | | |
| | 2.2 | Pathology and pathogenesis 2.2.1 Factors adverse to trypanosome survival | 10 | | |
| | | 2.2.2 Factors favouring trypanosome survival | 10 | | |
| | | 2.2.3 Nervous system dysfunction | 11 | | |
| | 2.3 | Diagnosis | 12 | | |
| | | 2.3.1 Detection of the parasite | 12 | | |
| | | 2.3.2 Indirect diagnosis | 14 | | |
| | 2.4 | Treatment | 15 | | |
| | 1 | 2.4.1 Recommended treatment | 16 | | |
| | | 2.4.2 Treatment of the first stage | 16 | | |
| | | 2.4.3 Treatment of the second stage | 17 | | |
| | | 2.4.4 Additional treatment | 18 | | |
| | | 2.4.5 Treatment of relapse in patients with <i>T. b. gambiense</i> | 40 | | |
| | | infection | 18 | | |
| | | 2.4.6 Treatment of relapse in patients with <i>T. b. rhodesiense</i> | 18 | | |
| | | infection | 18 | | |
| | | 2.4.7 Follow-up | 10 | | |
| 3. | The | parasite | 19 | | |
| | 3.1 | Taxonomy and nomenclature | 19 | | |
| | 3.2 | Characterization | 19 | | |
| | | 3.2.1 Biological and immunological characterization | 19 | | |
| | | 3.2.2 Biochemical and molecular characterization | 21 | | |
| | 3.3 | Isolation and preservation | 23 | | |
| | | 3.3.1 Methods of isolation | 23 | | |
| | | 3.3.2 Cryopreservation | 23 | | |
| | 3.4 | Metabolism | 23 | | |
| 4. | The vectors 24 | | | | |
| | 4.1 | Taxonomy and species identification | 24 | | |
| | 4.2 | Species distribution | 25 | | |
| | | Bioecology | 25 | | |
| | | 4.3.1 Reproduction | 25 | | |
| | | 4.3.2 Longevity | 26 | | |
| | | 4.3.3 Habitats | 26 | | |
| | | 4.3.4 Resting sites | 26 | | |
| | | 4.3.5 Feeding behaviour | 27 | | |
| | | 4.3.6 Dispersal | 27 | | |
| | | 4.3.7 Response to odours and colours | 27 | | |
| | 4.4 | Population dynamics | 28 | | |
| | 4.5 | Tsetse flies as vectors of trypanosomes | 28 | | |
| | | 4.5.1 Epidemiological risk factors | 28 | | |

| | | 4.5.2 Experimental studies of vector competence4.5.3 Vectorial capacity | 29 29 | | |
|----|--|--|----------|--|--|
| 5. | Dru | gs for the treatment of trypanosomiasis | 30 | | |
| | 5.1 | | 30 | | |
| | | 5.1.1 Pentamidine | 30 | | |
| | | 5.1.2 Suramin sodium | 32 | | |
| | 5.2 | Drugs for the treatment of the second stage | 33 | | |
| | | 5.2.1 Melarsoprol | 33 | | |
| | | 5.2.2 Eflornithine | 34 | | |
| | | 5.2.3 Nifurtimox | 36 | | |
| | | Combinations of drugs | 37 | | |
| | 5.4 5.5 | Drug resistance Prophylaxis | 37 37 | | |
| 6. | Epidemiology | | | | |
| | 6.1 | Transmission dynamics | 37 | | |
| | | 6.1.1 T. b. gambiense | 37 | | |
| | | 6.1.2 T. b. rhodesiense | 39 | | |
| | 6.2 | Reservoir hosts | 39 | | |
| | | 6.2.1 T. b. gambiense | 39 | | |
| | | 6.2.2 T. b. rhodesiense | 40 | | |
| | 6.3 | | 40 | | |
| | 6.4 | Indicators of transmission rates | 41 | | |
| | 6.5 | Factors influencing transmission rates | 42 | | |
| 7. | Pub | lic health aspects | 43 | | |
| | 7.1 | | 43 | | |
| | 7.2 | Social impact of the disease | 43 | | |
| | | 7.2.1 Individual and family level | 43 | | |
| | | 7.2.2 Community level | 44 | | |
| 8. | Control and surveillance | | | | |
| | 8.1 | Identification of cases in the population at risk | 45 | | |
| | | 8.1.1 Methods | 45 47 | | |
| | | 8.1.2 Case-detection strategies8.1.3 Options for control and surveillance | 48 | | |
| | 8.2 | Vector control | 51 | | |
| | 0.2 | 8.2.1 Principles and constraints | 51 | | |
| | | 8.2.2 Traps and screens | 52 | | |
| 9. | Tools for the implementation and evaluation of control programmes 55 | | | | |
| | 9.1 | Geographical information systems | 55 | | |
| | 9.2 | Decision analysis | 57 | | |
| | 9.3 | Definition of indicators for the evaluation of control programmes | 57 | | |
| | | 9.3.1 The scope of evaluation | 58 | | |
| | | 9.3.2 The use of indicators for programme improvement | 59 | | |
| | 9.4 | Financial and economic aspects | 59 | | |
| | | 9.4.1 Calculating the cost of case-detection and treatment | 59 | | |
| | | 9.4.2 Sampling strategies | 60 | | |

| 10. | Training and research | | | |
|------------|-------------------------------|--|----------------|--|
| | 10.1 | Training 10.1.1 Types of training 10.1.2 The approach to training | 60 61 61 | |
| | | 10.1.3 Training materials | 62 | |
| | 10.2 | Research | 62 | |
| | | 10.2.1 Epidemiological research 10.2.2 Research on tsetse flies | 62 62 | |
| | | 10.2.3 Research on drugs | 62 | |
| | | 10.2.4 Improvement of surveillance | 62 | |
| | | 10.2.5 Health systems research | 63 | |
| 11. | Reco | mmendations | 63 | |
| Ack | nowle | dgements | 65 | |
| References | | | | |
| Ann | ex 1 | | | |
| Exa | mples | of treatment schedules for sleeping sickness | 66 | |
| Ann | ex 2 | | | |
| | | gy and laboratory maintenance and designation procedures for bracei | 69 | |
| | | | | |
| | ex 3 o <mark>pres</mark> e | ervation of trypanosome-infected blood samples | 77 | |
| Ann | ex 4 | | | |
| | | ical information systems | 79 | |
| Ann | | | | |
| Trap | s and | screens for the control of Glossina spp. | 82 | |
| | ex 6 | of vector central energtions using transport | 00 | |
| Exa | mpies | of vector control operations using traps and screens | 88 | |
| Ann | | lo of decision analysis; the corresping process for African | | |
| | | le of decision analysis: the screening process for African miasis | 91 | |
| Ann | ex 8 | | | |
| | | of indicators for monitoring African trypanosomiasis control and be activities | 96 | |
| Ann | ex 9 | | | |
| | | of cost calculations for analysing the cost-effectiveness of | | |
| diffe | rent d | etection and treatment strategies | 100 | |